4-Borono-L-phenylalanine
4-Borono-L-phenylalanine structure
|
Common Name | 4-Borono-L-phenylalanine | ||
|---|---|---|---|---|
| CAS Number | 76410-58-7 | Molecular Weight | 209.01 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 449.3±55.0 °C at 760 mmHg | |
| Molecular Formula | C9H12BNO4 | Melting Point | 285-293ºC (dec.) | |
| MSDS | Chinese USA | Flash Point | 225.5±31.5 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Pharmacokinetic analysis and uptake of 18F-FBPA-Fr after ultrasound-induced blood-brain barrier disruption for potential enhancement of boron delivery for neutron capture therapy.
J. Nucl. Med. 55(4) , 616-21, (2014) Boronophenylalanine has been applied in clinical boron neutron capture therapy for the treatment of high-grade gliomas. The purpose of this study was to evaluate the pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine-fructose ((18)F-FBPA-Fr) in F98 g... |
|
|
Low dose of gamma irradiation enhanced boronophenylalanine uptake in head and neck carcinoma cells for boron neutron capture therapy.
Appl. Radiat. Isot. 69(12) , 1728-31, (2011) This study attempted to increase the boron uptake of human head and neck carcinoma SAS cells for BNCT by using a gamma dose of 0.1 Gy for combined treatment. Intracellular boron concentrations in 25 μgB/mL medium of BPA treated and BPA combined gamma-irradiat... |
|
|
Boron neutron capture therapy induces apoptosis of glioma cells through Bcl-2/Bax.
BMC Cancer 10 , 661, (2010) Boron neutron capture therapy (BNCT) is an alternative treatment modality for patients with glioma. The aim of this study was to determine whether induction of apoptosis contributes to the main therapeutic efficacy of BNCT and to compare the relative biologic... |
|
|
Studies for the application of boron neutron capture therapy to the treatment of differentiated thyroid cancer.
Appl. Radiat. Isot. 69(12) , 1752-5, (2011) The aim of these studies was to evaluate the possibility of treating differentiated thyroid cancer by BNCT. These carcinomas are well controlled with surgery followed by therapy with (131)I; however, some patients do not respond to this treatment. BPA uptake ... |
|
|
Boron neutron capture therapy for clear cell sarcoma (CCS): biodistribution study of p-borono-L-phenylalanine in CCS-bearing animal models.
Appl. Radiat. Isot. 69(12) , 1721-4, (2011) Clear cell sarcoma (CCS) is a rare melanocytic malignant tumor with a poor prognosis. Our previous study demonstrated that in vitro cultured CCS cells have the ability to highly uptake l-BPA and thus boron neutron capture therapy could be a new option for CCS... |
|
|
EORTC trial 11001: distribution of two 10B-compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial.
J. Cell. Mol. Med. 13(8B) , 1653-65, (2009) Boron neutron capture therapy (BNCT) provides highly targeted delivery of radiation through the limited spatial distribution of its effects. This translational research/phase I clinical trial investigates whether BNCT might be developed as a treatment option ... |
|
|
Metabolism of borono-phenylalanine-fructose complex (BPA-fr) and borocaptate sodium (BSH) in cancer patients--results from EORTC trial 11001.
J. Pharm. Biomed. Anal. 51(1) , 284-7, (2010) Within the clinical trial EORTC 11001, patients were infused with (10)B-enriched borono-phenylalanine-fructose complex (BPA-fr), or borocaptate sodium (BSH) solutions, which are used as boron carriers for boron neutron capture therapy. Urine samples were peri... |
|
|
A cancer research UK pharmacokinetic study of BPA-mannitol in patients with high grade glioma to optimise uptake parameters for clinical trials of BNCT.
Appl. Radiat. Isot. 67(7-8 Suppl) , S31-3, (2009) This paper describes results to-date from a human pharmacokinetic study which began recruitment in December 2007. Results are presented for a single patient recruited in December 2007. A second patient was recruited in July 2008 but detailed data are not avai... |
|
|
T2 corrected quantification method of L-p-boronophenylalanine using proton magnetic resonance spectroscopy for boron neutron capture therapy.
Appl. Radiat. Isot. 67(7-8 Suppl) , S345-7, (2009) In the present study, we aimed to evaluate a T2 corrected quantification method of l-p-boronophenylalanine (BPA) concentration using proton magnetic resonance spectroscopy (MRS). We used five phantoms containing BPA (1.5, 3.0, 5.0, 7.5, and 10 mmol/kg=15, 30,... |
|
|
Macro- and microdistributions of boron drug for boron neutron capture therapy in an animal model.
Anticancer Res. 32(7) , 2657-64, (2012) The boron concentration (BC) in the blood, rather than in normal tissue, is often used as the reference to calculate the BC in tumor for boron neutron capture therapy (BNCT). The aims of this study were to justify whether BC in the blood is equal to that of n... |